Combination therapy with brentuximab vedotin and gemcitabine in patients is “highly active” regimen for patients with Hodgkin lymphoma, the authors of a phase II clinical study report.
Combination therapy with brentuximab vedotin and gemcitabine in patients is “highly active” regimen for patients with Hodgkin lymphoma, the authors of a phase II clinical study report.